Astellas Pharma GmbH

DED2601V.HRB96767|Ridlerstr. 57, 80339 MünchenGermany|1991

Profit€22.3M

Revenue€802.1M

Employees239

Balance€321.4M

About

Tochtergesellschaft der Astellas Pharma Inc., spezialisiert auf den Vertrieb von pharmazeutischen Produkten in den Bereichen Onkologie, Transplantation, Urologie, Gastroenterologie, Frauengesundheit und Nephrologie.

Business purpose (commercial register)

Entwicklung, Herstellung und Vertrieb von sowie Handel mit pharmazeutischen, chemischen und im Zusammenhang mit dem Gesundheitssektor stehenden Produkten aller Art im In- und Ausland.

ClassificationWZ 2025

G.46.46.1 - Großhandel mit pharmazeutischen Erzeugnissen

Business Sectors

Onkologie607,2 Mio. €

Transplantologie69,4 Mio. €

Urologie18,8 Mio. €

Gastroenterologie11,3 Mio. €

Woman’s Health6,6 Mio. €

Nephrologie5,5 Mio. €

Antiinfektiva468.000,0 €

Products

Onkologie Transplantationsmedizin Medizin Gastroenterologie Gesundheit Nephrologie Antibiotika

Opportunities & Risks

Onkologie Wachstum Innovation Produkteinführung Pipeline Arzneimittel

Patente Preisdruck Regulierung Regulatorische Anforderungen Pharma Wettbewerbsdruck Abhängigkeitsrisiken

This summary was generated with the help of AI. See our Data Quality Notice. Report error?

Source: German Commercial Register (Handelsregister) München Local Court, HRB 96767 (as of 25 August 2026)

Company Structure

Shareholders

Name	Type	City
Dilek Cevik	Geschäftsführer(in)	Surrey
Grazyna Malkowska-Kicka	Geschäftsführer(in)	München
Jan Norden	Geschäftsführer(in)	Hällviken

Company	Location
Astellas Deutschland GmbH	München

Source: German Commercial Register (Handelsregister) München Local Court, HRB 96767 (as of 25 August 2026)

Company History

Management

Date	Event Type	Event
04.12.2018	Business Address Change	Ridlerstr. 57, 80339 München
06.10.2009	Business Address Registered	Georg-Brauchle-Ring 64-66, 80992 München
25.07.2006	Gesellschaftsvertrag amended	Gesellschaftsvertrag

Date	Type	Change	Total Capital
04.07.2005	Capital Increase	+500 €	14.000.500 €
24.10.2001	Capital Decrease	-13.000.000 €	14.000.000 €
16.10.2001	Share Capital Set	—	27.000.000 DM

CPV categories

Pharmaceutical products

Date	Contract	Role	Counterparty	Value
13.2.2026	34. Generikaausschreibung (1er) - Auftragsbekanntmachung Supplier · GWQ ServicePlus AG	Supplier	GWQ ServicePlus AG	—
22.5.2025	Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und der Astellas Pharma GmbH zu Evrenzo(R) Supplier · IKK classic	Supplier	IKK classic	—

Source: German Commercial Register (Handelsregister) München Local Court, HRB 96767 (as of 25 August 2026)

Financials

Key financial figures over time — Astellas Pharma GmbH
Year	Revenue	Profit	Balance	Employees
2025	€802,120,818	€22,265,899	€321,376,289	239
2024	€694,555,464	€19,237,681	€338,085,726	253
2023	€616,704,920	€6,115,144	€381,191,503	—
2022	€534,063,530	€24,493,017	€413,038,862	—
2021	€535,689,978	€25,064,499	€428,206,183	—
2020	€517,824,652	€32,911,052	€363,179,149	—
2019	€491,865,143	€26,887,524	€327,531,997	—
2018	€414,843,137	€40,525,362	€386,539,727	—
2016	€387,979,227	€37,445,575	€404,283,010	—
2015	€296,266,144	€77,974,240	€270,616,147	—

Source: German Company Register (Unternehmensregister)

Register Files

Current Printout (AD)

Chronological Printout (CD)

List of Shareholders

Articles of Association

Registration Application

Source: German Commercial Register (Handelsregister) München Local Court, HRB 96767 (as of 25 August 2026)

Similar Companies

ADELHEID GmbH

Alzenau · Großhandel mit pharmazeutischen Erzeugnissen

€878.2M

Novo Nordisk Pharma GmbH

Mainz · Großhandel mit pharmazeutischen Erzeugnissen

€949.8M

Gilead Sciences GmbH

Martinsried · Großhandel mit pharmazeutischen Erzeugnissen

€697.1M

Annual Financial Statements

Annual Report 2025Published on 21 October 2025

Consolidated Report 2024Published on 17 July 2025

Annual Report 2024Published on 1 April 2025

Annual Report 2023Published on 10 March 2025

Consolidated Report 2023Published on 16 July 2024

Annual Report 2022Published on 12 May 2023

Consolidated Report 2022Published on 27 March 2023

Consolidated Report 2021Published on 10 May 2022

Annual Report 2021Published on 19 April 2022

Annual Report 2020Published on 23 June 2021

Consolidated Report 2020Published on 18 March 2021

Annual Report 2019Published on 10 March 2021

Consolidated Report 2019Published on 18 December 2020

Consolidated Report 2018Published on 28 May 2019

Consolidated Report 2017Published on 17 July 2018

Consolidated Report 2016Published on 23 June 2017

Annual Report 2016Published on 16 May 2017

Consolidated Report 2015Published on 25 July 2017

Annual Report 2015Published on 31 May 2016

Consolidated Report 2014Published on 19 July 2017

Annual Report 2014Published on 28 April 2015

Consolidated Report 2013Published on 31 July 2017

Annual Report 2013Published on 13 May 2014

Consolidated Report 2012Published on 24 July 2017

Annual Report 2012Published on 4 June 2013

Annual Report 2011Published on 11 May 2012

Annual Report 2010Published on 21 April 2011

Annual Report 2009Published on 23 April 2010

Annual Report 2008Published on 27 August 2009

Annual Report 2007Published on 17 October 2008

Annual Report 2006Published on 25 March 2008

Annual Report 2005Published on 25 March 2008

Annual Report 2004Published on 18 April 2008

Source: German Company Register (Unternehmensregister)

Cost type	Amount	Share
Cost of Goods Sold	€206,737,819	62.4%
Selling Costs	€32,325,732	9.8%
Admin Costs	€13,050,767	3.9%
R&D Costs	€79,129,288	23.9%

Astellas Pharma GmbH

About

Business purpose (commercial register)

ClassificationWZ 2025

Business Sectors

Products

Opportunities & Risks

Company Structure

Company History

Financials

Register Files

Similar Companies

Annual Financial Statements

Cost Distribution (2005)

Trends